Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Frank Bennett

Showing results (161-170 of 169) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 169 results.
Nature Medicine|October 16, 2023
Author Correction: Tau-targeting antisense oligonucleotide MAPT<sub>Rx</sub> in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trialCatherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, et al.
The New England Journal of Medicine|July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALSTimothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Journal of Medicinal Chemistry|October 1, 2004
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replicationAnne B Eldrup, Marija Prhavc, Jennifer Brooks, et al.
Cell Metabolism|January 18, 2016
Deletion or Inhibition of the Oxygen Sensor PHD1 Protects against Ischemic Stroke via Reprogramming of Neuronal MetabolismAnnelies Quaegebeur, Inmaculada Segura, Roberta Schmieder, et al.
Nature Medicine|April 24, 2023
Tau-targeting antisense oligonucleotide MAPT<sub>Rx</sub> in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trialCatherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2013
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degenerationClotilde Lagier-Tourenne, Michael Baughn, Frank Rigo, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Therapeutic targeting of alternative splicing caused by a lethal noncoding structural variant in X-linked dystonia parkinsonismRachita Yadav, Christine A Vaine, Aloysius Domingo, et al.
Lancet (London, England)|May 25, 2025
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case seriesNeil A Shneider, Matthew B Harms, Vlad A Korobeynikov, et al.
Neuron|April 27, 2016
Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAsJie Jiang, Qiang Zhu, Tania F Gendron, et al.
Pageof 17

Showing results (161-170 of 169) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 169 results.
Nature Medicine|October 16, 2023
Author Correction: Tau-targeting antisense oligonucleotide MAPT<sub>Rx</sub> in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trialCatherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, et al.
The New England Journal of Medicine|July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALSTimothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Journal of Medicinal Chemistry|October 1, 2004
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replicationAnne B Eldrup, Marija Prhavc, Jennifer Brooks, et al.
Cell Metabolism|January 18, 2016
Deletion or Inhibition of the Oxygen Sensor PHD1 Protects against Ischemic Stroke via Reprogramming of Neuronal MetabolismAnnelies Quaegebeur, Inmaculada Segura, Roberta Schmieder, et al.
Nature Medicine|April 24, 2023
Tau-targeting antisense oligonucleotide MAPT<sub>Rx</sub> in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trialCatherine J Mummery, Anne Börjesson-Hanson, Daniel J Blackburn, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2013
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degenerationClotilde Lagier-Tourenne, Michael Baughn, Frank Rigo, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Therapeutic targeting of alternative splicing caused by a lethal noncoding structural variant in X-linked dystonia parkinsonismRachita Yadav, Christine A Vaine, Aloysius Domingo, et al.
Lancet (London, England)|May 25, 2025
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case seriesNeil A Shneider, Matthew B Harms, Vlad A Korobeynikov, et al.
Neuron|April 27, 2016
Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAsJie Jiang, Qiang Zhu, Tania F Gendron, et al.
Pageof 17